Company: SHPH
Filing Date: 2025-01-24
Form Type: 424B3
Source: 0001493152-25-003508
Chunk: 157

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-01-24
Form: 424B3
Chunk 157
---
 99 |

| ● | any                                                                                                                                 
 transaction involving the corporation that has the effect of increasing the proportionate share of the stock or any class or series 
 of the corporation beneficially owned by the interested stockholder; or                                                             |
| ● | the                                                                                                                                 
 receipt by the interested stockholder of the benefit of any loss, advances, guarantees, pledges or other financial benefits by or   
 through the corporation.                                                                                                            |

Section 203 defines interested stockholder as an entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation or any entity or person affiliated with or controlling or controlled by such entity or person.

Nasdaq Listing

Our shares of common stock are traded on The Nasdaq Capital Market under the symbol “SHPH.” We do not intend to apply for listing of the Warrants on any securities exchange or other nationally recognized trading system.

Transfer Agent

The transfer agent and registrar of our common stock is VStock Transfer, LLC, of Woodmere, New York. Our transfer agent’s telephone number is (212) 828-8436.

Trading Market

Our common stock is listed on the Nasdaq Capital Market under the symbol “SHPH.” We do not intend to apply for listing of the Warrants on any securities exchange or other nationally recognized trading system.

<div align='center'>SHARES ELIGIBLE FOR FUTURE SALE</div>

Sales of a substantial number of shares our common stock in the public market, or the perception that such sales could occur, could adversely affect the public price of our common stock and may make it more difficult for you to sell your shares at a time and price that you deem appropriate. We will have no input if and when the Selling Stockholders may, or may not, elect to sell the shares of common stock covered by this prospectus or the prices at which any such sales may occur.

As of January 10, 2025, a total of 4,076,568 shares of our common stock were outstanding. All of the shares of common stock being registered for resale under the registration statement of which this prospectus forms a part will be freely tradable in the public market without restriction or further registration under the Securities Act, unless these shares are held by “affiliates,” as that term is defined in Rule 144 under the Securities Act. Any shares not registered hereunder or pursuant to another registration statement will be “restricted securities,” as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible